Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...

The global composite decking market size is estimated to grow by USD 3.99 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 16.6% during the forecast ...

The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.

Check the time stamp on this data. Updated AI-Generated Signals for Arrowhead Pharmaceuticals Inc. (ARWR) available here: ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...